Addressing Challenges in Cell Therapy Manufacturing

Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.

Cancer research has come a long way. Along with technology advancements, the basic options for treating cancer, such as surgery, radiation, and chemotherapy, have expanded their mainstays when immunotherapy is developed. Individualised CAR-T cell therapy uses a patient’s immune system to fight specific types of cancers or a broad spectrum of immuno-oncology and infectious diseases. Cell-based therapies aim to treat diseases by altering or restoring certain sets of cells or using cells to carry a therapy through the body.

Despite substantial progress in this field, cell therapy manufacturing presents multiple challenges that must be addressed as production scales up. At Agilent, our cell analysis team works closely with cell therapy manufacturing companies to explore innovative technologies that can overcome some of these challenges locally, regionally, and globally.